75%Confidence
0Views
FDASource
2026-03-30Date
Summary
Harvard Drug Group's packaging defect for Midodrine tablets highlights potential supply chain vulnerabilities in blister packaging operations that could affect multiple products. This Class II recall may indicate broader quality control issues at Major Pharmaceuticals' packaging facility.
Actionable: Monitor for potential follow-up recalls from the same packaging facility.
AI Confidence: 75%
Data Points
firmThe Harvard Drug Group LLC
classificationClass II
statusOngoing
distributionNationwide US.
productMidodrine Hydrochloride Tablets, USP, 5 mg, 50 Tablets (5 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapol
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now